Effectiveness and safety of CD22 and CD19 dual‐targeting chimeric antigen receptor T‐cell therapy in...
Effectiveness and safety of CD22 and CD19 dual‐targeting chimeric antigen receptor T‐cell therapy in patients with relapsed or refractory B‐cell malignancies: A meta‐analysis
About this item
Full title
Author / Creator
Publisher
Bognor Regis: John Wiley & Sons, Inc
Journal title
Language
English
Formats
Publication information
Publisher
Bognor Regis: John Wiley & Sons, Inc
Subjects
More information
Scope and Contents
Contents
Background
The efficacy of CD22 or CD19 chimeric antigen receptor T (CAR‐T) cells in the management of acute lymphoblastic leukemia (ALL) and non‐Hodgkin lymphoma (NHL) was observed. Because antigen loss and lack of CAR‐T‐cell persistence are the leading causes of progressive disease following single‐antigen targeting, we evaluated CD22/CD19 dua...
Alternative Titles
Full title
Effectiveness and safety of CD22 and CD19 dual‐targeting chimeric antigen receptor T‐cell therapy in patients with relapsed or refractory B‐cell malignancies: A meta‐analysis
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_14150acabd0f40c0b61dbd02d0da9fd2
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_14150acabd0f40c0b61dbd02d0da9fd2
Other Identifiers
ISSN
2045-7634
E-ISSN
2045-7634
DOI
10.1002/cam4.6497
